Table 1.
Descriptive statistics and missing data patterns of fluoxetine and venlafaxine trials at baseline. Not available (NA) indicate trials where the depression measure was not used.
| Trial | CDRS (SD) | HDRS (SD) | Age (range) | Male (%) | Duration (wks) | No. Assess. | n |
|---|---|---|---|---|---|---|---|
| TADS fluoxetine | 56 (10.8) | NA | 13 (8–18) | 51 | 9 | 7 | 221 |
| Eli Lilly fluoxetine 1 | 44 (12.1) | NA | 11 (7–18) | 72 | 3 | 3 | 219 |
| Eli Lilly fluoxetine 2 | 58 (10.3) | NA | 13 (7–18) | 54 | 8 | 9 | 172 |
| Eli Lilly fluoxetine 3 | 55 (12.8) | NA | 15 (12–18) | 47 | 12 | 3 | 96 |
| Eli Lilly fluoxetine 4 | NA | 22 (3.5) | 16 (12–17) | 45 | 6 | 7 | 40 |
|
Calibration Trials | |||||||
| Wyeth venlafaxine 1 | 54 (8.7) | 18 (5.1) | 12 (7–17) | 51 | 8 | 8 | 167 |
| Wyeth venlafaxine 2 | 58 (9.2) | 16 (4.8) | 12 (7–18) | 58 | 8 | 8 | 191 |
TADS: Treatment for Adolescents With Depression Study